Home › Compare › EDRWY vs ABBV
EDRWY yields 2.69% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, EDRWY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of EDRWY + ABBV for your $10,000?
Electric Power Development Co., Ltd. engages in the wholesale supply of hydroelectric and thermal power in Japan. The company operates through Electric Power Business, Overseas Business, Electric Power-Related Business, and Other Business segments. It also produces wood fuel and other biomass fuels; and generates and transmits electricity. In addition, the company invests in, imports, transports, and sells coal; sells fly ash; procures forest offcut; produces and sells fertilizers; offers activated coke; operates welfare, wood pellet manufacturing, and nuclear power plants; operates and maintains telecommunication facilities and waste-fueled power generation plants; and constructs and maintains electronic and communication facilities. Further, it engages in the ocean transportation of coal for thermal power plants; research, planning, and analysis of environmental conservation; surveying and compensation for construction sites; provision of investment management, and research and development of projects; facility maintenance and business process outsourcing activities; development of computer software; and ocean transportation of ash and fly ash. Additionally, the company provides civil engineering, and construction management and services; and engineering services for atmospheric and water pollutant removal equipment. Further, it is involved in the consulting business. The company has 60 hydroelectric power plants with a total capacity of 8,560 MW; 13 thermal power generation facilities with a total capacity of 9,200 MW; 21 wind power facilities with a total capacity of 500 MW; 1 geo-thermal facility with a total capacity of 23 MW; and 2,410.1 kilometers of power transmission lines, and 9 substations and converter stations, as well as operates 33 power generation facilities with a total capacity of 6,523 MW located in Thailand, the United States, China, and internationally. The company was incorporated in 1952 and is headquartered in Tokyo, Japan.
Full EDRWY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.